Clearside Biomedical (CLSD) Issues Earnings Results
Clearside Biomedical (NASDAQ:CLSD) announced its quarterly earnings results on Thursday. The company reported ($0.75) EPS for the quarter, missing analysts’ consensus estimates of ($0.63) by ($0.12), Fidelity Earnings reports.
Shares of NASDAQ CLSD traded down $0.14 during mid-day trading on Friday, reaching $1.84. 707,532 shares of the company were exchanged, compared to its average volume of 703,408. The company has a debt-to-equity ratio of 0.15, a quick ratio of 7.94 and a current ratio of 7.94. The stock has a market cap of $70.13 million, a PE ratio of -0.79 and a beta of -3.98. Clearside Biomedical has a twelve month low of $1.83 and a twelve month high of $15.33.
A number of analysts have commented on the stock. Zacks Investment Research upgraded shares of Clearside Biomedical from a “sell” rating to a “hold” rating in a research note on Monday, August 13th. Wedbush set a $29.00 price target on shares of Clearside Biomedical and gave the company a “buy” rating in a research note on Wednesday, August 8th. Cowen cut shares of Clearside Biomedical from an “outperform” rating to a “market perform” rating in a research note on Monday, November 5th. BidaskClub cut shares of Clearside Biomedical from a “buy” rating to a “hold” rating in a research note on Friday, July 20th. Finally, Laidlaw assumed coverage on shares of Clearside Biomedical in a research note on Monday, July 16th. They issued a “buy” rating and a $18.00 price target for the company. Three analysts have rated the stock with a sell rating, two have given a hold rating and six have given a buy rating to the company’s stock. Clearside Biomedical presently has an average rating of “Hold” and a consensus price target of $12.71.
About Clearside Biomedical
Clearside Biomedical, Inc, a late-stage clinical biopharmaceutical company, develops pharmacological therapies to treat blinding diseases of the eye. It is developing suprachoroidal injection of CLS-TA, a proprietary preservative-free formulation of the corticosteroid triamcinolone acetonide, which is in Phase III clinical trial for the treatment of macular edema associated with non-infectious uveitis; suprachoroidal injection of CLS-TA and a concomitant intravitreal injection of Eylea, an inhibitor of vascular endothelial growth factor that is in Phase III clinical trial to treat macular edema associated with retinal vein occlusion; and suprachoroidal injection of CLS-TA alone or together with intravitreal injection of Eylea that is in phase II clinical trial for diabetic macular edema.
Receive News & Ratings for Clearside Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clearside Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.